Background
Angiosarcoma (AS) is a rare and highly malignant type of soft tissue sarcoma derived from vascular endothelial cells. It accounts for only 1-4% of all soft tissue sarcomas. 1, 2 Clinical symptoms vary considerably based on the primary sites including the skin, soft tissue and viscera. For example, patients with cutaneous ASs usually present bruise-like patches, violaceous nodules or plaques, 3 whereas symptoms of visceral ASs include abdominal pain, hepatosplenomegaly or anemia. 4 The prognosis for primary AS is generally poor. Previous studies have addressed the poor prognosis of AS of the face and scalp (ASFS) which is a particular subgroup of sarcomas characterized by high frequencies of local recurrence or distant metastasis, with a 5-year survival rate of 11.1-53.8%. 5 Due to a low rate of clinical suspicion and unusual clinical presentation, a significant portion of patients present inoperable AS or metastasis at the time of initial diagnosis. 4, 6, 7 Surgery was considered the initial treatment, but was also observed with high rates of local recurrence. 8 Although the most effective treatments for the primary AS should vary according to individuals, the multimodal treatment (surgery followed by chemotherapy and/or radiotherapy) is considered the optimal option. 3, 9 However, the majority of patients will ultimately develop distant metastases even after treatment, with local or systemic failure approaching 70% of all cases of complete resections. 4, [10] [11] [12] [13] It was reported that the rupture of cystic metastases in the lung would cause repeated pneumothorax and hemothorax and was the major cause of death. 14, 15 Several tumor biomarkers such as platelet-derived growth factor receptor-β and vascular endothelial growth factor receptor-2 have been investigated about their correlations with AS prognosis. 16 However, detecting these biomarkers as routine clinical tests is not feasible due to the high cost and absence of standardization system. Therefore, it is intriguing to identify a set of accessible biomarkers to predict prognosis before treatment. Recently, pretreatment systemic inflammatory indexes including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and monocyte-to-lymphocyte ratio (MLR) have been reported to be associated with the prognosis of soft tissue sarcomas. [17] [18] [19] Owing to the extreme rarity of this tumor, reports on clinicopathological features and prognostic factors of primary angiosarcoma (PAS) are limited and most of them are case reports or small case series, of which the selection bias makes the results difficult to interpret. Gen Suzuk et al have investigated the role of 3 inflammatory markers in prognosis of 17 patients with AS. 20 Our study aims to identify a set of accessible biomarkers in patients' peripheral blood and clarify their relationships with the overall survival (OS 
Statistical analysis
NLR, PLR, MLR, SII, LDH and ALP were calculated with receiver operating curves (ROC) to determine the optimal cutoff values and then dichotomized into 2 categories: less than, and greater than or equal to the cutoff values. Survival curves were obtained by Kaplan-Meier survival analysis and compared among groups by log-rank test.
Only variables revealing significant association on univariate analyses (p<0.10) were then performed with multivariate analyses. Multivariate analyses were performed using Cox proportional hazards regression, reported with 95% CIs to estimate the association between variables and survival outcome. All the statistical analyses were performed using SPSS version 21.0, and p<0.05 was considered statistically significant in multiple cox regression analyses.
Results

Baseline characteristics
This study analyzed 56 patients pathologically confirmed of AS treated at West China Hospital between 2010 and 2017. Table 2 and Figure 1 . By analyzing the specificity and sensitivity of each value, the optimal cutoff Abbreviations: NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio; SII, systemic immune-inflammation index; LDH, lactate dehydrogenase. Abbreviations: NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio; SII, systemic immune-inflammation index; LDH, lactate dehydrogenase; ROC, receiver operating curve. (Figure 2 ). Multivariate analysis was accordingly performed to identify any independent prognostic factors for AS. After being adjusted by other potential factors including the tumor grade, size, MLR and surgical history, high levels of pretreatment NLR (HR 2.673, 95% CI 1.253-5.703, p=0.011) and LDH (HR2.964, 95% CI 1.464-5.998, p=0.003) were proved to be independent predictors of poor survival outcomes (Table 3) .
Discussion
To the best of our knowledge, this is the first study to explore the prognostic value of a set of pretreatment inflammatory indexes including NLR, PLR, MLR, SII, LDH and ALP, in a relatively large clinical setting of 56 patients with this rare sarcoma. There was only one study specifically targeting AS which evaluated the prognostic role of 3 serum markers in 17 patients with ASFS. 20 The OS of AS patients at any location was relatively short 21 and the major problem is the absence of treatment standards. Based on the histopathology of PAS, some studies have suggested the concomitant use of antiangiogenic agents such as bevacizumab with chemotherapy 22 and that the molecular disorders like p53, PI3K, or mTOR pathways observed in PAS patients would be a future research direction. 23 Consistent with previous studies, 24-27 the head and neck (33.9%) and viscera (organs and bones) were two most common sites for AS. One of the previous studies suggested that breast ASs had better survival than other parts of AS, 3 whereas in some other studies of breast AS, 28,29 such favorable survival could not be observed. Our results demonstrated the visceral AS was associated with the worst prognosis with a median OS of 14.6 months, which is in accordance with the research of Fayette et al. 4 Therefore, further studies are warranted to assess the correlation of tumor sites with AS prognosis. Interestingly, although our univariate analysis demonstrated that patients with high tumor grade had a poor prognosis with a median OS of 16.3 months compared with 51.7 months in patients with low & intermediate grade, the multivariate analysis failed to identify significant differences. This finding is in accordance with a previous study 11 in 1996 which reported the association of tumor grades with survival outcomes, but only in univariate analyses. However, some studies have suggested contrary results that the grade is not a prognostic factor for PAS. 30 Furthermore, the tumor size has been considered as a hallmark of AS prognosis, with previous evidence suggesting that tumor larger than 5 cm predicts poor prognosis. 11, [31] [32] [33] [34] We found that patients with tumors ≥5 cm had a median survival of 16.3 months vs 31.5 months of tumors <5 cm. Currently, the radical surgery remains the primary treatment modality for this highly malignant sarcoma, with other treatments such as chemotherapy or radiotherapy concomitantly used under certain circumstances. Our results showed the prolonged survival of patients receiving surgery (32.9 months vs 12.4 months without surgery). Although it was reported that the survival of malignant vascular tumors was related to complete surgical resection, 35 the aggressive nature of AS made it difficult to completely clear surgical margins. The values of neutrophil, platelet and lymphocyte, monocyte, LDH and ALP values can be easily obtained with minimally invasive procedures. Recently, these markers have been evaluated in many studies to predict the prognosis in patients with various types of cancer including hepatocellular carcinoma, renal cell carcinoma, lung cancer, urinary cancer and colorectal cancer. [36] [37] [38] [39] [40] [41] These markers such as NLR, PLR and MLR are believed to reflect the interplay between the systemic inflammatory responses with the tumor microenvironment. Elevated NLR, PLR and MLR are able to increase the resting energy expenditure, hypoalbuminemia and malnutrition, which ultimately leads to weight loss and tumor progression. 42, 43 The exact mechanisms of this interaction remain incompletely defined. One possible explanation is that neutrophilia is related to the inhibition of cytotoxic activity of T cells and NK cells and at the same time lymphocyte infiltration has been shown to promote an effective antitumor cellular immune response. [44] [45] [46] In this study, the multivariate analyses identified pretreatment NLR (HR 2.673, 95% CI 1.253-5.703, p=0.011) and LDH (HR 2.964, 95% CI 1.464-5.998, p=0.003) levels as independent indicators for AS prognosis. One limitation of the present study is the number of patients enrolled. Owing to its extreme rarity, previous reports on AS could only reach a relatively small patient group and their results often lack consensus. In this study, the reason why prognostic values of tumor grade and size failed to reach statistical significance in multivariate analyses might be the limited number of primary AS patients. Further studies involving larger patient groups are therefore required. In addition, we were unable to retrieve patients' TNM staging. Staging of AS follows the TNM system for soft tissue sarcoma by American Joint Committee on Cancer. However, because AS represents a unique type of all sarcomas, and there is no standardized treatment regime for each specific stage, TNM staging is of little benefit in clinical practice. 47 
Conclusion
In summary, AS is an extremely rare type of cancer with poor prognosis. This study identifies pretreatment serum levels of NLR and LDH as clinically useful markers to predict survival in patients with PAS. In addition, although survival curves suggested that patients with surgical treatment, low tumor grade and small tumor size have prolonged OS, the difference failed to reach statistical significance in multivariate analyses. Future studies involving larger patient groups with longer follow-up periods are warranted to verify the results.
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